Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200-Day Moving Average – Here’s What Happened

Atossa Genetics Inc. (NASDAQ:ATOS) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.99 and traded as low as $1.9250. Atossa Genetics shares last traded at $1.93, with a volume of 73,866 shares.

Wall Street Analyst Weigh In

ATOS has been the subject of a number of recent analyst reports. Ascendiant Capital Markets cut their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a report on Friday, April 10th. Weiss Ratings lowered Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Finally, HC Wainwright increased their price target on Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Atossa Genetics currently has a consensus rating of “Hold” and an average target price of $24.50.

Atossa Genetics Price Performance

The business’s 50 day moving average price is $4.30 and its 200 day moving average price is $5.99. The firm has a market cap of $16.62 million, a PE ratio of -0.60 and a beta of 1.24.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12). As a group, analysts predict that Atossa Genetics Inc. will post -4.3 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Genetics

A number of large investors have recently modified their holdings of ATOS. &PARTNERS purchased a new position in shares of Atossa Genetics in the fourth quarter worth about $25,000. Hudson Bay Capital Management LP acquired a new stake in Atossa Genetics in the 2nd quarter valued at about $26,000. JPMorgan Chase & Co. lifted its stake in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after purchasing an additional 144,412 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.